4713 studies found for:    "Leukemia"
Show Display Options
Rank Status Study
21 Terminated
Has Results
5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Intervention: Drug: 5-Azacytidine
22 Withdrawn Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Chronic Lymphocytic Leukemia
Intervention: Drug: Oral Clofarabine
23 Terminated Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia
Conditions: B-cell Chronic Lymphocytic Leukemia;   Leukemia;   Prolymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Drug: obatoclax mesylate;   Drug: fludarabine phosphate;   Biological: rituximab;   Other: laboratory biomarker analysis
24 Not yet recruiting Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Venetoclax
25 Terminated Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Conditions: Minimal Residual Disease;   Leukemia, Lymphoblastic, Acute;   Leukemia, Myelogenous, Acute
Interventions: Drug: Clofarabine;   Drug: Cytarabine;   Drug: Methotrexate
26 Terminated Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Intervention: Drug: Clofarabine
27 Terminated
Has Results
Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia
Conditions: Large Granular Lymphocytic Leukemia;   LGL Leukemia
Interventions: Drug: Cyclosporine;   Genetic: Gene expression analysis;   Genetic: Microarray analysis;   Other: Laboratory biomarker analysis
28 Completed
Has Results
Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older
Conditions: Leukemia;   CLL;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: Lenalidomide
29 Recruiting Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Chronic Lymphocytic Leukemia
Interventions: Drug: Nivolumab;   Drug: Ibrutinib
30 Active, not recruiting Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Rituximab
31 Recruiting A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Interventions: Drug: Ibrutinib;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Rituximab
32 Recruiting Trial of Immune Reconstitution With Activated T-Cells Following Lymphodepleting Chemotherapy in Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Chronic Lymphocytic Leukemia
Interventions: Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Fludarabine monophosphate;   Drug: Bendamustine;   Biological: Activated T-Cell Infusion;   Drug: Lenalidomide;   Behavioral: Phone Calls
33 Active, not recruiting AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Prolymphocytic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   Testicular Lymphoma;   Waldenstrom Macroglobulinemia
Interventions: Other: Pharmacodynamic Studies;   Other: Fatigue Inventory;   Other: Pharmacogenomic studies;   Drug: AR-42
34 Recruiting First-line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Chronic Lymphocytic Leukemia
Interventions: Drug: Obinutuzumab;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Ibrutinib;   Drug: Allopurinol;   Drug: Valacyclovir
35 Terminated Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
Conditions: Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: Bendamustine Hydrochloride;   Biological: Alemtuzumab
36 Completed A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies
Conditions: Lymphoma, Mantle-cell;   Leukemia, Lymphocytic, Chronic, B-Cell;   Leukemia, Hairy Cell;   Waldenstrom Macroglobulinemia;   Multiple Myeloma
Intervention: Drug: ON01910 Na
37 Terminated SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Blastic Phase Chronic Myelogenous Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes
Intervention: Drug: SJG-136
38 Terminated Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia
Conditions: Acute Leukemias of Ambiguous Lineage;   Acute Undifferentiated Leukemia;   Angioimmunoblastic T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Small Intestine Lymphoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: dexrazoxane hydrochloride;   Drug: doxorubicin hydrochloride;   Drug: obatoclax mesylate;   Drug: liposomal vincristine sulfate;   Other: pharmacological study;   Other: laboratory biomarker analysis
39 Terminated A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell;   Chronic Lymphocytic Leukemia;   Lymphoma, Small Lymphocytic
Intervention: Drug: Lenalidomide, Rituximab, and Cyclophosphamide
40 Completed Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Basophilic Leukemia;   Adult Acute Eosinophilic Leukemia;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Blastic Phase Chronic Myelogenous Leukemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts in Transformation;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes
Interventions: Drug: tanespimycin;   Drug: cytarabine

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years